In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Microbix Biosystems Inc.

Latest From Microbix Biosystems Inc.

Zydus gets rights to re-launch, manufacture Microbix's urokinase

The Canadian firm, Microbix Biosystems, has licensed all rights and expertise concerning its thrombolytic drug, Kinlytic (urokinase), to Zydus Cadila under a milestone-cum-royalty-based pact that aims to reintroduce the product in North America.


Deals Shaping The Medical Industry (03/2012)

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Zydus to back Microbix's urokinase relaunch plans in North America

The Canadian firm, Microbix Biosystems, will receive financial backing and regulatory support from Zydus Cadila of India for the proposed relaunch of the thrombolytic drug, urokinase, in the North America.

Infectious Diseases India

$250 million Canada-China flu vaccine JV stalls after spat over deal renegotiation

The future looks uncertain for a joint venture that had been limbering up to build Asia's largest influenza vaccine facility in Hunan province, China. One of the joint venture partners, Canadian firm Microbix Biosystems, says it has suspended all activity and returned finances raised from private investors in January, after running into an impasse in negotiations with its Chinese partner over amendments to the deal they originally signed in 2008.

Infectious Diseases China
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
  • Medical Devices
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cardiovascular
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • Canada
  • Parent & Subsidiaries
  • Microbix Biosystems Inc.
  • Senior Management
  • Cameron Groome, Pres. & CEO
    Jim Currie, CFO
    Mark A Cochran, PhD, CBO
    Philip J Casselli, SVP, Bus. Dev., Sales & Mktg.
    Kenneth Hughes, PhD, COO
  • Contact Info
  • Microbix Biosystems Inc.
    Phone: (905) 361-8910
    265 Watline Ave.
    Mississauga, L4Z 1P3